This week, we will be starting therapy using the new FDA approved protease inhibitors, Victrelis (boceprevir) and Incivek (telaprevir) in our patients with chronic hepatitis C.
Below is a brief podcast explaining some of the procedures required prior to initiating therapy with these new agents.
Listen to the podcast here: Hepatitis C Treatment Introduction
Call our office at 713-794-0700 if you have questions.
Liver Specialists of Texas
6624 Fannin, Suite 1990
Houston, TX 77030